Ampio pharmaceuticals inc - more than 350 patients have now reached ap-013 study's 12-week primary endpoint

Ampio provides update on ap-013 phase iii clinical trial and annual meeting conference call number.ampio pharmaceuticals inc - as of december 3, 2019, of 1,034 patients to be enrolled in ap-013.ampio pharmaceuticals inc - more than 350 patients have now reached ap-013 study's 12-week primary endpoint.ampio pharma - on october 22, independent safety monitoring committee completed a confidential review of results from first 300 randomized subjects.ampio pharmaceuticals inc - as a result of review, current safety profiles of ampion and placebo injections are similar.ampio pharmaceuticals inc - study investigators have identified no remarkable safety findings.
AMPE Ratings Summary
AMPE Quant Ranking